Device-Associated Infections in COVID-19 Patients: Frequency of Resistant Bacteria, Predictors and Mortality in Medellín, Colombia

Overview

Journal Microorganisms

Specialty Microbiology

Date 2024 Apr 27

PMID 38674585

Authors

Diana Patricia Ocampo

Lina Maria Echeverri-Toro

Judy Natalia Jimenez

Lorena Salazar

Carlos Vargas

Gustavo Roncancio

Maria Alejandra Roa

Johanna Marcela Vanegas

Affiliations

Soon will be listed here.

Abstract

Introduction: Increased antimicrobial use during the COVID-19 pandemic has raised concerns about the spread of resistant bacteria. This study analyzed the frequency of device-associated infections (DAI) caused by resistant bacteria, the predictors of these infections, and 30-day all-cause mortality in patients with and without COVID-19.

Methods: A retrospective cohort study was conducted on DAI patients admitted to the ICU (intensive care unit) in 20 hospitals in Medellin, Colombia (2020-2021). The exposure assessed was the COVID-19 diagnosis, and outcomes analyzed were resistant bacterial infections and 30-day mortality. Clinical and microbiological information was collected from surveillance databases. Statistical analysis included generalized linear mixed-effects models.

Results: Of the 1521 patients included, 1033 (67.9%) were COVID-19-positive and 1665 DAI were presented. Carbapenem-resistant (CRE) infections predominated during the study (n = 98; 9.9%). The patients with COVID-19 had a higher frequency of metallo-beta-lactamase-producing CRE infections (n = 15; 33.3%) compared to patients without the disease (n = 3; 13.0%). Long-stay in the ICU (RR: 2.09; 95% CI: 1.39-3.16), diabetes (RR: 1.73; 95% CI: 1.21-2.49), and mechanical ventilation (RR: 2.13; 95% CI: 1.01-4.51) were CRE infection predictors in COVID-19 patients, with a mortality rate of 60.3%.

Conclusion: CRE infections were predominant in COVID-19 patients. In pandemic situations, the strategies to control DAI should be maintained to avoid infections caused by resistant bacteria, such as length of stay in the ICU and duration of mechanical ventilation.

References

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Fernandez-Garcia O, Gonzalez-Lara M, Villanueva-Reza M, de-Leon-Cividanes N, Xancal-Salvador L, Esteban-Kenel V . Outbreak of NDM-1-Producing Escherichia coli in a Coronavirus Disease 2019 Intensive Care Unit in a Mexican Tertiary Care Center. Microbiol Spectr. 2022; 10(1):e0201521. PMC: 8754109. DOI: 10.1128/spectrum.02015-21. View

Murray A . The Novel Coronavirus COVID-19 Outbreak: Global Implications for Antimicrobial Resistance. Front Microbiol. 2020; 11:1020. PMC: 7237633. DOI: 10.3389/fmicb.2020.01020. View

Rezasoltani S, Yadegar A, Hatami B, Aghdaei H, Zali M . Antimicrobial Resistance as a Hidden Menace Lurking Behind the COVID-19 Outbreak: The Global Impacts of Too Much Hygiene on AMR. Front Microbiol. 2021; 11:590683. PMC: 7769770. DOI: 10.3389/fmicb.2020.590683. View

Santoro A, Franceschini E, Meschiari M, Menozzi M, Zona S, Venturelli C . Epidemiology and Risk Factors Associated With Mortality in Consecutive Patients With Bacterial Bloodstream Infection: Impact of MDR and XDR Bacteria. Open Forum Infect Dis. 2020; 7(11):ofaa461. PMC: 7652098. DOI: 10.1093/ofid/ofaa461. View

Grasselli G, Scaravilli V, Mangioni D, Scudeller L, Alagna L, Bartoletti M . Hospital-Acquired Infections in Critically Ill Patients With COVID-19. Chest. 2021; 160(2):454-465. PMC: 8056844. DOI: 10.1016/j.chest.2021.04.002. View

Monnet D, Harbarth S . Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance?. Euro Surveill. 2020; 25(45). PMC: 7667630. DOI: 10.2807/1560-7917.ES.2020.25.45.2001886. View

Falcone M, Tiseo G, Giordano C, Leonildi A, Menichini M, Vecchione A . Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. J Antimicrob Chemother. 2020; 76(4):1078-1084. PMC: 7799007. DOI: 10.1093/jac/dkaa530. View

Lansbury L, Lim B, Baskaran V, Lim W . Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020; 81(2):266-275. PMC: 7255350. DOI: 10.1016/j.jinf.2020.05.046. View

10.

Blot S, Ruppe E, Harbarth S, Asehnoune K, Poulakou G, Luyt C . Healthcare-associated infections in adult intensive care unit patients: Changes in epidemiology, diagnosis, prevention and contributions of new technologies. Intensive Crit Care Nurs. 2022; 70:103227. PMC: 8892223. DOI: 10.1016/j.iccn.2022.103227. View

11.

Tamma P, Goodman K, Harris A, Tekle T, Roberts A, Taiwo A . Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia. Clin Infect Dis. 2016; 64(3):257-264. PMC: 5241781. DOI: 10.1093/cid/ciw741. View

12.

Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M . Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2020; 27(1):83-88. PMC: 7836762. DOI: 10.1016/j.cmi.2020.07.041. View

13.

Mahoney A, Safaee M, Wuest W, Furst A . The silent pandemic: Emergent antibiotic resistances following the global response to SARS-CoV-2. iScience. 2021; 24(4):102304. PMC: 7955580. DOI: 10.1016/j.isci.2021.102304. View

14.

Cox M, Loman N, Bogaert D, OGrady J . Co-infections: potentially lethal and unexplored in COVID-19. Lancet Microbe. 2020; 1(1):e11. PMC: 7195315. DOI: 10.1016/S2666-5247(20)30009-4. View

15.

Rawson T, Ming D, Ahmad R, Moore L, Holmes A . Antimicrobial use, drug-resistant infections and COVID-19. Nat Rev Microbiol. 2020; 18(8):409-410. PMC: 7264971. DOI: 10.1038/s41579-020-0395-y. View

16.

Wang Z, Yang B, Li Q, Wen L, Zhang R . Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020; 71(15):769-777. PMC: 7184452. DOI: 10.1093/cid/ciaa272. View

17.

Peleg A, Hooper D . Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010; 362(19):1804-13. PMC: 3107499. DOI: 10.1056/NEJMra0904124. View

18.

Nebreda-Mayoral T, Miguel-Gomez M, March-Rossello G, Puente-Fuertes L, Canton-Benito E, Martinez-Garcia A . Bacterial/fungal infection in hospitalized patients with COVID-19 in a tertiary hospital in the Community of Castilla y León, Spain. Enferm Infecc Microbiol Clin (Engl Ed). 2022; 40(4):158-165. PMC: 8847094. DOI: 10.1016/j.eimce.2022.02.002. View

19.

Ruiz-Garbajosa P, Canton R . COVID-19: Impact on prescribing and antimicrobial resistance. Rev Esp Quimioter. 2021; 34 Suppl 1:63-68. PMC: 8683018. DOI: 10.37201/req/s01.19.2021. View

20.

Nori P, Szymczak W, Puius Y, Sharma A, Cowman K, Gialanella P . Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients. Int J Antimicrob Agents. 2020; 56(6):106179. PMC: 7518801. DOI: 10.1016/j.ijantimicag.2020.106179. View